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Abstract
Background: Fluorescence optical imaging (FOI) enables visualization of inflammation in the hands in rheumatic
joint diseases with currently a lack of long-term follow-up studies.
Objective: To investigate FOI for treatment monitoring in a homogenous cohort of patients with early (disease
duration < 2 years) and active (DAS28 > 3.2) RA over a period of 12 months.
Methods: Thirty-five RA patients (24 (68.6%) females, mean age 53.3 years (SD 13.6)) were investigated clinically by
DAS28, tender joint count (TJC) and swollen joint count (SJC) and by FOI in phases 1–3 and PrimaVistaMode (PVM)
before therapy change and after 12 months. The FOI activity score (FOIAS) was calculated based on individual joint
scores from 0 to 3 in 30 joints per patient, adding up to a sum score (0–90).
Results: We found a statistically significant reduction of FOIAS in phase 1 from baseline (median 5.0, IQR 24.96) to
follow-up (median 1.0, IQR 4.0) in all patients (p = 0.0045), both in responders and non-responders according to
EULAR response criteria by DAS28. Statistically significant reductions over 12 months were found for median
DAS28(ESR) 5.61 to 3.31, TJC 7.0 to 1.0, and SJC 5.0 to 1.0 (each p < 0.001). No statistically significant correlations
were detected between the FOIAS change in phase 1 and DAS28(ESR), TJC, or SJC. Correlations between the other
phases and clinical outcomes were weak to moderate.
Conclusion: Reduced early enhancement in FOI phase 1 can be observed in clinically responding and non-
responding early RA patients under treatment. Regarding potential marker performance, FOI probably shows a
reduction of inflammation more objectively.
Keywords: Arthritis, rheumatoid, Fluorescence, Ultrasonography, Follow-up studies
Background
To monitor therapeutic response in patients with rheuma-
toid arthritis (RA), clinical disease activity scores such as
DAS28 are applied [1]. Besides, more sensitive and object-
ive imaging modalities are recommended in the clinical
management of RA [2]. Magnetic resonance imaging
(MRI) and musculoskeletal ultrasound (US) are both
widely used in clinical practice and research within the
field of RA [3–8]. MRI-detected pathologies such as syno-
vitis and tenosynovitis are highly responsive to antirheu-
matic treatment [9–11]. However, MRI has the
disadvantage of high costs, time exposure, and occasional
contraindications (e.g., pacemaker and claustrophobia)
[12]. In several studies, US-detected synovitis and teno-
synovitis have also been shown to be sensitive to change
under therapy, especially in Power Doppler mode (PDUS)
[13–16] reflecting disease activity. US is a cost-effective,
widespread method that is risk-free for patients, is indefin-
itely repeatable, and involves less inconvenience than
MRI. Drawbacks may be the dependency on the examiner
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[17] and the inability to pairwise compare baseline and
follow-up images immediately while investigating unless
all images are saved for analysis later on; however, US im-
ages are usually saved as “still images” (lost of dynamic
approach).
In search of an imaging method for the optimal detec-
tion of disease activity, new procedures are developed and
investigated. Since 2009, the fluorescence optical imaging
(FOI) “Xiralite” (Xiralite GmbH, Berlin, Germany) has
been shown to detect inflammation in preclinical studies
[18, 19] as well as in humans [20–26] in the joint regions
of both hands. The basis of the Xiralite method is the
demonstration of an impaired microcirculation caused by
the inflammatory process of arthritis. Here, the enhance-
ment of an intravenously applied dye indocyanine green
(ICG) is evaluated. FOI is a non-ionizing technique that
examines both hands in one session of 6 min. Besides, the
examination itself can be performed by clinical assistants.
Impediments in the sense of resulting contraindications
are an impaired liver function, since the applied dye is pri-
marily excreted biliarily [27]. Furthermore, an allergic re-
action to the ICG solution can occur [28]. However, the
overall risk of ICG to the patient is low [29].
Previous studies have demonstrated good agreements
between FOI, clinical assessment, MRI, and US [21] as
well as a moderate und substantial reliability for the scor-
ing of FOI images [22]. Additionally, FOI may also detect
subclinical inflammation [25]. Only one study has evalu-
ated the responsiveness of FOI, so far. Meier et al. found a
reduction in the signal intensity during therapy response
in a group of patients with forms of different arthritis who
were examined by a computer-based evaluation of FOI
and MRI; however, the observed group was heterogeneous
and only investigated over a time period of 6months [30].
The aim of the present study was the investigation of
FOI’s ability to reflect treatment response in a
homogenous cohort of patients with early and active RA
over a period of 12 months. Besides, we aimed for ex-
ploration of its correlations with clinical outcomes such
as DAS28. The correlation with US as a common im-
aging modality in daily rheumatological practice was set
as a secondary outcome.
Methods
This study is a subproject (No. 7) of the Arthromark pro-
ject as a national research network in Germany funded by
the Federal Ministry of Education and Research (BMBF).
The main goal of the several Arthromark subprojects is
the identification of new biomarkers including the applica-
tion and assessment of new and modern imaging tech-
niques in terms of making a diagnosis and follow-up
examinations in patients with RA, psoriasis arthritis, and
spondyloarthritis [31].
In this subproject, we included 42 patients with early (dis-
ease duration < 24months) and active (DAS28 > 3.2) RA,
who started therapy with conventional synthetic disease-
modifying antirheumatic drugs (csDMARDs) or escalated
therapy with initiation of biologic therapy (bDMARD) after
failure of conventional therapy. Over a period of 1 year, pa-
tients were examined clinically and by US (for further de-
scription of additional US, see Additional file 1) five times
(baseline, after 6 weeks, and 3, 6, and 12months). FOI was
performed at baseline and after 12months in 35 patients
who were included in these analyses (in seven patients, the
12-month visit was not performed).
Clinical and laboratory examination
A clinical assessment of tender (28 tender joint count
(TJC)) and swollen joints (28 swollen joint count (SJC))
was performed. Patients self-reported their evaluation of
the global disease activity and the current general joint
pain (both on a visual analog scale (VAS) 0–100mm).
Clinical and laboratory examination was accomplished
on the same day as the imaging (FOI; US) examinations.
Usually, FOI was ordinarily performed after the US
examination. The laboratory investigation included the
assessment of erythrocyte sedimentation rate (ESR) and
C-reactive protein (CRP). The rheumatoid factor (RF)
and anti-citrullinated peptide antibodies (ACPA) were
determined at inclusion.
The Disease Activity Score DAS28 was calculated
based on the 28-TJC, 28-SJC, ESR or CRP, and patient’s
global VAS [1]. The calculation of the difference be-
tween DAS28 value at baseline or the prior visit and
current value gave information of response to therapy
after EULAR response criteria [32–34] (a definition is
presented in Additional file 1: Table S1). Based on the
EULAR response (Table S1), patients were assigned to a
group of responders (DAS28(ESR) ≤ 3.2 and improve-
ment of > 0.6) or non-responders (DAS28(ESR) > 3.2).
This process was done to evaluate treatment monitoring
by FOI.
Fluorescence optical imaging (FOI)
FOI (Xiralite® System) was performed following a stan-
dardized procedure.
The examination term lasted 6 min, recording one
image per second and adding up to a cluster of 360 images
[21, 22]. A bolus of indocyanine green (ICG) as fluores-
cence optical dye with a dose of 0.1 mg/kg body weight
was injected intravenously 10 s after the beginning of the
examination [21, 22].
The attached software system enabled a visualization of
invasion and distribution of ICG in the hands. An image
sequence in the film modus and an automatically gener-
ated image in the PrimaVistaMode (PVM) were analyzed
to evaluate the distribution and enhancement of ICG. For
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the film modus, three phases in position to the fingertips
were defined regarding signal intensities depending on in-
dividual perfusion [22]. Phase 1 (p1) included the period
between starting the investigation, application of the dye,
and increased signal intensities in the fingertips [22],
which means an increasing intensity of fluorescence sig-
nal. The time period of persisting high signal intensities as
plateau in the fingertips was defined as phase 2 (p2) [22].
Investigators do identify this phase on red color signs of
the enhancement in the fingertips. The time point without
signal intensity meaning only yellow sparkles in the finger-
tips as a signal for clearance determined the beginning of
phase 3 (p3) [22].
Enhancement of ICG can be graded by false-color illus-
tration, which is identical between different scans, time
points, and patients. It defines white enhancement as high
intensities and concentration of ICG. Red, yellow, and
green enhancement follows in a descending order of ICG
concentration. For analyzing the joint activity by FOI, the
evaluation at the joint level included a combination of size,
shape, and color of the signal in a semiquantitative grading
system (FOIAS; fluorescence optical imaging activity score):
0 = no signal enhancement, green to yellow signals; 1 = low
signal intensity (≤ 25% of the joint area affected), yellow-red
signals including red signals with yellow spots; 2 =moderate
signal intensity (> 25%, ≤ 50% of the joint area affected),
strong red signals including red signals with white spots;
3 = strong signal intensity (> 50% of the joint area affected),
white signals [21, 22]. If there was a discrepancy between
the intensity of the color and the size of the enhancement,
the lower grade of the scoring system was assigned. In de-
tail, enhancements with a discrepancy between two subse-
quent grades (1 and 2 or 2 and 3) were evaluated with the
lower grade number. Differences of signal color and size be-
tween grades far apart (e.g., grades 1 and 3) were scored
with the intermediate grade (e.g., grade 2).
The ICG distribution in the three phases (p1, p2, p3)
and in PrimaVistaMode (PVM) was assessed for the joint
regions of 30 joints per patient, including the bilateral
wrist, metacarpophalangeal joints (MCP) I–V, proximal
interphalangeal joints (PIP) II-V, distal interphalangeal
joints (DIP) II-V, and interphalangeal joint of the thumb
(IP) [21]. The scoring of color intensity, size, and shape of
ICG enhancement was performed by an agreement-based
consensus of two investigators (SO; LS).
We calculated the number of affected joints and sum
scores (FOIAS; fluorescence optical imaging activity
score) for each phase (0–90 scales). In addition, the sum
scores of the left hand and the right hand were individu-
ally calculated.
Statistical analyses
Wilcoxon signed rank tests were done to compare clinical
data (TJC, SJC, DAS28(ESR)) and FOIAS between two
visits (baseline (V0) and 12months (V12)). Furthermore,
Mann-Whitney U tests were performed to test for the stat-
istical significance of the difference of score change between
responders and non-responders to DAS28 changes under
treatment. In addition, we examined whether the FOIAS
was correlated with clinical outcome and ultrasound data
by use of Spearman’s correlation coefficients including the
analysis assessing specific points of time and the change be-
tween two points of time. The significance level of 0.05
(5%) was used. p values were not adjusted for multiple test-
ing due to the explorative character of the analyses. Statis-
tical analyses were performed with the statistical program R
[35]. If not specified otherwise, the descriptive statistics pro-
vided median values (1. quartile; 3. quartile).
Results
Patients’ characteristics are presented in Table 1. Our
analyses focused on the 35 of 42 patients who completed
the study after 12 months.
Clinical parameters
During 12months follow-up, we found statistically sig-
nificant reductions in TJC 7.0 (3.5;15) to 1.0 (0;3) and
SJC 5.0 (3;9.5) to 1.0 (0;2), respectively (each p < 0.001;
see Table 2).
At baseline, patients had high disease activity with me-
dian DAS28(ESR) of 5.61 (4.8;6.23). After 1 year, disease
activity was statistically significantly reduced to a median
DAS28 of 3.31 (2.45;3.98) (p < 0.001) which corresponds
to moderate disease activity (see Table 2). By the end of
the study, 31.4% (11/35) of patients had achieved remis-
sion (DAS28 < 2.6).
Fluorescence optical imaging (FOI)
Statistically significant reductions were detected in the
FOI sum score (FOIAS) in phase 1 from baseline (5.0,
(1.04; 26)) to 12months follow-up (1.0 (0; 4)) in the total
patient cohort (p = 0.0045). There were no statistically sig-
nificant changes in the FOI sum score in phase 2, phase 3,
or PVM in the total cohort (see Table 3 and Fig. 1 and
Additional file 1: Table S2 (analysis without DIP).
Correlation of FOI and clinical parameters
Regarding baseline data, no significant positive correl-
ation between FOI and clinical parameters (TJC, SJC,
and DAS28(ESR)) can be shown (see Fig. 2a).
FOI in phase 1 showed no statistically significant corre-
lations with clinical data concerning the analysis of clinic-
ally affected joints and FOI after 12months follow-up (see
Fig. 2b). FOI phases 2 and 3 demonstrated weak to mod-
erate correlations with DAS28(ESR) and SJC. PVM corre-
lated significantly with all three clinical parameters. While
the correlation with TJC was only weak (r = 0.38), PVM
correlated moderately with SJC and DAS28(ESR) (r = 0.58,
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r = 0.51, see Fig. 2b). The corresponding p values of the
correlation coefficients were < 0.05. An additional statis-
tical analysis performed without the DIP joints in FOI did
not change the level or direction of correlation (for further
data see Additional file 1: Tables S3a-b).
Correlations between FOI and US
US data of baseline and after 12 months are presented in
Table 2.
With respect to the calculated correlations in the total
group, tenosynovitis in greyscale ultrasound (GSUS) and
PDUS correlated with every phase and PVM at baseline,
but strongest for PD-tenosynovitis with phase 2 (r = 0.73;
p < 0.05). With regard to GS- and PD-synovitis, signifi-
cant positive correlations with phase 1, phase 2, and PVM
at baseline can be shown. While GS-synovitis
most strongly correlated with PVM in FOI (r = 0.6), the
strongest correlation between PD-synovitis and FOI was
demonstrated for phase 1 (r = 0.59) (Fig. 3a).
After 12months, FOI in phase 2 demonstrated the stron-
gest correlations, especially with PD-tenosynovitis (r = 0.63;
p < 0.05) and GS-tenosynovitis (r = 0.59; p < 0.05). For
phase 1, low correlation with GS-synovitis can be demon-
strated (r = 0.48, p < 0.05). However, PVM was the only FOI
part correlating with all considered US parameters (Fig. 3b).
Comparison of clinical findings and FOI in responders vs.
non-responders
According to the EULAR response criteria [32], n = 16
(45.7%) patients were defined as responders (DAS28(ESR)
≤ 3.2 and improvement of > 0.6) and n = 19 (54.3%) as
non-responders (DAS28(ESR) > 3.2).
Table 1 Patients’ characteristics at baseline
Summary statistics
Age (n = 35) At the beginning of the study 53.32 (13.63)
(22.23;74)
Number of patients ≥ 65 years (LORA) 8/35 (22.86%)
Gender (n = 35) Female 24/35 (68.57%)
Disease duration (n = 35) Duration from initial diagnosis until inclusion
in the study (in months)
0.2 (0.42)
(0;1.98)
Duration of symptoms (in months) 1.3 (1.25)
(0.13;4.5)
Disease Activity Score 28 (DAS28) DAS28(ESR) (n = 34) 5.55 (1.11)
(3.55;7.57)
DAS28(CRP) (n = 31) 5.02 (1.12)
(3.09;6.77)
Laboratory parameters ESR (1 h/mm) (n = 34) 39.62 (22.23)
(8;95)
CRP (n < 5.0 mg/l) (n = 32) 16.34 (17.89)
(0;66.52)
Clinical examination (n = 35) Swollen joint count (28-SJC) 6.31 (4.73)
(1;20)
Tender joint count (28-TJC) 10.26 (7.85)
(1;25)
VAS (0–100mm) for disease activity Patient (n = 35) 58.14 (18.79)
(20;100)
Physician (n = 21) 54.52 (16.58)
(30;90)
Rheumatoid factor (RF) Seropositive (n = 34) 15/35 (42.86%)
Rheumatoid factor IgA (n = 29) 93.23 (166.03)
(0.1;500)
Rheumatoid factor IgM (n = 31) 59.64 (113.93)
(0.1;500)
Anti-citrullinated peptide
antibodies (ACPA) (n = 35)
Level 250.34 (393.27)
(0.42;1000)
Positive 4/35 (11.43%)
Highly positive 15/35 (42.86%)
Patients’ characteristics at baseline: mean (SD); (min; max) or n (%); DAS28 Disease Activity Score of 28 joints, ESR erythrocyte sedimentation rate, CRP
C-reactive protein
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Regarding the responders (DAS28(ESR) ≤ 3.2 and im-
provement of > 0.6; n = 16) and non-responders
(DAS28(ESR) > 3.2; n = 19), both groups demonstrated a
statistically significant decline in affected tender and swol-
len joints after 12months. Non-responders had a greater
number of tender (11 (5.5;18.5)) and swollen (6; (3.5;9.5))
Table 2 Clinical and ultrasound parameters at baseline and after 12 months in total population, group of responders and non-
responders
Month of visit
0 (V0)*
Month of visit
12 (V12)*
Difference between
V12 and V0*
p value (Wilcoxon
signed rank test)
Total population (n = 35 for clinical, n = 34 for US7 parameters)
28-SJC 5 (3;9.5)
(1;20)
1 (0;2)
(0;10)
−4 (−7;− 1)
(−19;3)
< 0.001 (sig.)
28-TJC 7 (3.5;15)
(1;25)
1 (0;3)
(0;26)
−4 (− 10;− 1)
(−24;6)
< 0.001 (sig.)
DAS28(ESR) 5.61 (4.8;6.23)
(3.55;7.57)
3.31 (2.45;3.98)
(1.13;6.19)
−2.22 (−3.11;− 1.39)
(−5.45;0.56)
< 0.001 (sig.)
GS-synovitis 7 (5.5;9.5)
(2;15)
6 (4.25;7)
(2;10)
− 1 (−3;0)
(−9;7)
0.0112 (sig.)
GS-tenosynovitis 3 (2;4)
(0;5)
2.5 (2;3)
(0;4)
−0.5 (−1.75;0)
(−4;2)
0.0239 (sig.)
PD-synovitis 4 (3;7)
(2;15)
3 (2;3.75)
(0;11)
−1 (−3;0)
(−9;1)
0.00004 (sig.)
PD-tenosynovitis 3 (2;4)
(0;7)
2 (1.25;3)
(0;5)
0 (−2;0.75)
(−4;1)
0.0163 (sig.)
Group of responders (n = 16)
28-SJC 3.5 (1.75;8.25)
(1;15)
0 (0;1)
(0;3)
−3.5 (−8.25;− 1) (−14;1) 0.002 (sig.)
28-TJC 4.5 (3;10.5)
(1;24)
0 (0;0.25)
(0;2)
−3.5 (−10.5;− 3) (−24;− 1) < 0.001 (sig.)
DAS28(ESR) 4.88 (4.33;6.18)
(3.55;7.33)
2.38 (1.89;2.68)
(1.13;3.18)
−2.82 (−3.82;− 1.82)
(−5.45;− 1.14)
< 0.001 (sig.)
GS-synovitis 8 (6;9.25)
(2;12)
6 (4;7)
(3;9)
−2 (−4.25;0)
(−9;7)
0.038 (sig.)
GS-tenosynovitis 4 (2.75;5)
(1;5)
2.5 (2;3)
(1;4)
−1 (−2;0)
(−4;2)
0.0274 (sig.)
PD-synovitis 4 (3.75;6.5)
(2;11)
3 (2;3)
(1;4)
−2 (−5;− 0.75)
(−8;1)
0.0028 (sig.)
PD-tenosynovitis 3 (2;5)
(1;7)
2 (2;3)
(1;3)
−1 (−2.25;0)
(−4;1)
0.01 (sig.)
Group of non-responders (n = 19 for clinical, n = 18 for US7 parameters)
28-SJC 6 (3.5;9.5)
(1;20)
1 (0;4)
(0;10)
−5 (−6.5;− 2)
(−19;3)
0.001 (sig.)
28-TJC 11 (5.5;18.5)
(1;25)
3 (1.5;11)
(0;26)
−4 (−8;0.5)
(−22;6)
0.01 (sig.)
DAS28(ESR) 5.82 (5.34;6.23)
(3.61;7.57)
3.95 (3.51;5.21)
(3.28;6.19)
−1.62 (−2.61;− 0.51)
(−3.73;0.56)
< 0.001 (sig.)
GS-synovitis 7 (4.5;9.5)
(2;15)
6 (5;8.5)
(2;10)
−1 (−2;0.75)
(−5;6)
0.1641
GS-tenosynovitis 2 (2;4)
(0;5)
2.5 (1;3)
(0;4)
0 (−1;1)
(−3;2)
0.506
PD-synovitis 4 (2.5;7)
(2;15)
3 (1;5)
(0;11)
−1 (−2;0)
(−9;1)
0.0058 (sig.)
PD-tenosynovitis 2 (1;3)
(0;7)
2.5 (1;3)
(0;5)
0 (−0.75;1)
(−4;1)
0.7732
Clinical and ultrasound (US) parameters at baseline and after 12 months in total population, group of responders and non-responders: *Median (1. quartile; 3.
quartile); (min; max), significance level = 0.05; 28-SJC swollen joint count of 28 joints, 28-TJC tender joint count of 28 joints, DAS28(ESR) Disease Activity Score of 28
joints and erythrocyte sedimentation rate (ESR), GS greyscale mode in ultrasound, PD Power Doppler mode in ultrasound
Glimm et al. Arthritis Research & Therapy          (2019) 21:209 Page 5 of 12
joints at baseline than the group of responders (TJC: 4.5 (3;
10.5) and SJC: 3.5 (1.75;8.25), respectively). After 12
months, the number of tender and swollen joints decreased
to 0 in responders (see Table 2). In non-responders, the
median number of tender joints and swollen joints was 3
(1.5;11) and 1 (0;4), respectively (see Table 2).
With regard to US7 score parameters, the group of re-
sponders showed significant decrease in all US7 parame-
ters, while the group of non-responders revealed
significant decrease only in PD-synovitis.
We found no statistically significant difference in the
change of the FOI sum score between responders and
non-responders for the FOI phases 2 and 3 and PVM re-
lating to EULAR response criteria [32–34] for low dis-
ease activity. In FOI phase 1, the difference in the
change of FOI sum score was similar in non-responders
(p = 0.047) and responders (p = 0.052) (see Fig. 4a).
There were no statistically significant differences across
patients who did vs. did not achieve remission for FOI
phases 2 and 3 and PVM. For FOI phase 1, statistically
Table 3 FOIAS of phases 1–3 and PVM (PrimaVistaMode) in FOI at baseline and after 12 months (n = 35 for FOIAS parameters
Month of visit
0 (V0)*
Month of visit
12 (V12)*
Difference between
V12 and V0*
p value (Wilcoxon
signed rank test)
Phase 1 5 (1.04;26)
(0;70.91)
1 (0;4)
(0;32)
−3 (− 17;0)
(−69.91;12)
0.00445 (sig.)
Phase 2 16 (10.5;25)
(1;40)
16 (9.5;24)
(2;43)
2 (−4.5;6.81)
(− 18;18)
0.6004
Phase 3 1 (0;2.5)
(0;15)
1 (0;4)
(0;10)
0 (− 1;1.5)
(− 12;9)
0.5451
PVM 9 (4.5;13)
(0;24)
9 (3.5;14)
(0;26)
−1 (−4;4)
(− 15;14)
0.7461
Phases 1–3 and PVM (PrimaVistaMode) of FOI at baseline and after 12 months (n = 35): FOIAS fluorescence optical imaging activity score; *median (1. quartile; 3.
quartile); (min; max); significance level = 0.05
Fig. 1 Reduction of early enhancement in FOI (fluorescence optical imaging) phase 1 after 12 months follow-up: a V0: Example with early high
enhancement in phase 1 before ICG flooding in the fingertips, especially in the wrists, PIPs, and IPs of both hands. Moderate enhancement in
MCP II and IV of the right hand. V12: High physiological enhancement in the fingertips in phase 1 after 12 months. No enhancement in the finger
and hand joints. b Example of early enhancement in phase 1 in both hands, especially in MCP II and III of the right hand. High enhancement also
in PIPs of both hands, left wrist, and MCP II and III. Physiological signal in the fingertips. V12: High physiological enhancement in the fingertips in
phase 1 after 12 months. No significant enhancement in the finger and hand joints. V0: baseline, V12: follow-up after 12 months
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significant difference was shown only in responders re-
garding clinical remission status (see Fig. 4b).
Discussion
To our knowledge, this present study is the first one de-
scribing the changes of FOI in a homogeneous cohort of
patients with early and active RA over a period of 12
months under antirheumatic therapy.
Regarding clinical and laboratory disease activity,
DAS28 decreased from high disease activity (DAS28 =
5.61) to moderate (DAS28 = 3.31) over the time period
described. 31.4% of patients (n = 16) achieved remission
of DAS28 < 2.6 under antirheumatic therapy.
Concerning FOI, we found significant reductions in the
FOI sum score in phase 1 in the total cohort, whereas the
other phases remained stable. These results are in line
with previous results by Meier et al., who found a signifi-
cant reduction in early signal intensity after 24 weeks of
therapy using a computer-based evaluation of FOI [30]. In
a study by Werner et al., phase 1 featured the highest
Fig. 2 Pairwise correlation between the number of affected joints in clinical examination and FOI phases 1, 2, and 3 and PVM: significance level =
0.05; FOI = fluorescence optical imaging; PVM = PrimaVistaMode; SJC = swollen joint count; TJC = tender joint count; DAS28(ESR) = Disease Activity
Score of 28 joints and erythrocyte sedimentation rate (ESR); VAS = visual analog scale. Spearman’s correlation coefficients and p values are
presented. a measurement at V0 (baseline) b change at V12 (12 months follow-up)
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agreement between clinical examination and FOI. In
addition, the highest specificity was calculated for phase 1
compared to MRI and US in this study [21], which was
also confirmed by Krohn et al. [24]. Besides, phase 1 did
not show any pathological changes in a healthy cohort,
confirming the hypothesis that this early phase reflects ac-
tive inflammation with increased vascularization and
therefore high clinical disease activity [21]. In a previous
study, we examined FOI in patients with either osteoarth-
ritis (OA) or RA. OA patients showed significantly less ac-
tivity in phase 1 (maximum degree 1), but a consistently
high signal accumulation in phase 2 (especially in the
wrist) [26]. These results support the hypothesis that
phase 1 detects an active inflammation [21, 22] since OA
is usually characterized by a less pronounced inflamma-
tion as compared to systemic inflammatory joint diseases.
In our analysis, we did not find a significant correl-
ation between the change of phase 1 and joint count.
The lack of correlations between phase 1 and clinical pa-
rameters may be due to different parameters we assess
in clinical examination and FOI. While we investigate a
disturbed microcirculation in FOI, we document mor-
phological changes in swollen fingers as a result of infil-
trated cells in the synovial membrane and pannus. The
impaired microcirculation visualized by FOI comprises
neoangiogenesis, hyperperfusion, and capillary leakage
Fig. 3 Pairwise correlation between US7 and FOI phase 1, 2, and 3 and PVM: significance level = 0.05; FOI = fluorescence optical imaging; PVM =
PrimaVistaMode; PD = power Doppler mode in ultrasound, GS = greyscale mode in ultrasound. Spearman’s correlation coefficients and p values
are presented. a measurements at V0 (baseline) b change at V12 (12 months follow-up)
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within the inflammatory process of RA [36]. It may be
assumed that both pathologies (microcirculation and
morphological changes) within the articular region ap-
pear on different time points in the disease course. On
the other hand, neoangiogenesis is an important compo-
nent in the formation of pannus and, therefore, not only
found around the inflamed joint [36]. Another explan-
ation for the lack of correlation may be false-positive
findings of FOI. However, Werner et al. demonstrated a
low rate of false-positive findings between 0.5 and 5% by
FOI [22]. Thus, our results stand in contrast to the results
by Werner et al. who presented good agreement rates and
low, but significant, correlations between FOI and clinical
examination. It should be noted that FOI detects any in-
flammation including scratches, plaques, and insect bites.
On this account, the evaluation requires a well-trained in-
vestigator [22]. However, the localization, form, and tem-
poral distribution of enhancement in the individual FOI
phases allow a differentiation [22] and may indicate the
underlying pathology or possible disease [26].
In addition, Werner et al. suggested divergence between
local inflammation in the hand and systemic inflammation
[21]. Furthermore, high variance for components of the
DAS28 was recently described [37], while FOI is a more
objective technical tool.
After 1 year under csDMARD or bDMARD therapy, ap-
proximately 46% of the patients in our study achieved a
clinical response stage according to the EULAR response
criteria [32–34] and showed a reduction in disease activity
according to the treat-to-target principle (T2T). The
change in FOI sum scores was similar in patients with and
without a clinical response. The significant reductions in
phase 1 also in non-responders probably show a more ob-
jective reduction of inflammation by FOI, while the clinical
non-response can also depend on individual person-related
(i.e., psychological) factors which may lead to elevated glo-
bal disease activity on VAS. Recently, Hammer et al.
showed no association between tender joints and synovitis
in GSUS and PDUS, while a strong correlation between
swollen joints and US synovitis was calculated. In addition,
they found a primary associationn between tender joints
and patient-reported joint pain [38]. These findings support
that the parameters of DAS28 hardly correlated with the
sum scores of FOI also in this present study. Similar results
for FOI were published by Werner et al. assuming different
characteristics of pathologies [21].
We conducted correlation analyses between musculoskel-
etal ultrasound and FOI findings. At baseline examination,
strong correlations were found between all FOI phases and
the ultrasound parameters, especially tenosynovitis in
PDUS. The strongest correlations were found for FOI
phase 2 at both baseline and after 12months of therapy. In
contrast, phase 1 did only show a positive correlation with
synovitis in GSUS after 12 months follow-up. The meaning
of phase 2 as a marker of subclinical activity has already
been discussed in previous studies [21, 22, 24]; however, no
longitudinal data exist yet showing a predictive value of
phase 2, for example in terms of erosive disease or flare pre-
diction. The strong signal accumulation could be caused by
increased vascularization due to chronic inflammation. The
low correlations of phase 1 with US at month 12 may indi-
cate that there was no or only a small amount of acute in-
flammation after 1 year of intensive therapy, whereas the
greyscale US synovitis findings can persist. FOI phase 1 is
probably a reflection of acute inflammation. A good re-
sponse of early enhancement in FOI to therapeutic inter-
ventions demonstrated by Meier et al. showed a decrease
of early signal intensity after 6months in response to ther-
apy [30].
Conclusions
In conclusion, activity in FOI phase 1 changed signifi-
cantly over 1 year under therapy in the group of re-
sponders regarding the parameter of clinical remission
(DAS28). However, a significant change of FOI phase 1
was also observed in non-responders, so we cannot ob-
jectively deduce a therapy response of phase 1. However,
the correlation of FOI with ultrasound as a validated and
well-established imaging technique in daily rheumato-
logical practice should be emphasized. In the issue, the
role of FOI in therapy monitoring needs to be investi-
gated in further studies.
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